Cargando…
Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence
With emerging information about the potential for morbidity and reduced life expectancy with long-term use of opioids, it is logical to evaluate nonopioid analgesic treatments to manage pain states. Combinations of drugs can provide additive and/or synergistic effects that can benefit the management...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150009/ https://www.ncbi.nlm.nih.gov/pubmed/35645354 http://dx.doi.org/10.3390/neurolint14020035 |
_version_ | 1784717331101908992 |
---|---|
author | Edinoff, Amber N. Fort, Juliana M. Singh, Christina Wagner, Sarah E. Rodriguez, Jessica R. Johnson, Catherine A. Cornett, Elyse M. Murnane, Kevin S. Kaye, Adam M. Kaye, Alan D. |
author_facet | Edinoff, Amber N. Fort, Juliana M. Singh, Christina Wagner, Sarah E. Rodriguez, Jessica R. Johnson, Catherine A. Cornett, Elyse M. Murnane, Kevin S. Kaye, Adam M. Kaye, Alan D. |
author_sort | Edinoff, Amber N. |
collection | PubMed |
description | With emerging information about the potential for morbidity and reduced life expectancy with long-term use of opioids, it is logical to evaluate nonopioid analgesic treatments to manage pain states. Combinations of drugs can provide additive and/or synergistic effects that can benefit the management of pain states. In this regard, tetrahydrocannabinol (THC) and cannabidiol (CBD) modulate nociceptive signals and have been studied for chronic pain treatment. Psilocybin, commonly known as “magic mushrooms”, works at the serotonin receptor, 5-HT(2A). Psilocybin has been found in current studies to help with migraines since it has a tryptamine structure and works similarly to triptans. Psilocybin also has the potential for use in chronic pain treatment. However, the studies that have looked at alternative plant-based medications such as THC, CBD, and psilocybin have been small in terms of their sample size and may not consider the demographic or genetic differences in the population because of their small sample sizes. At present, it is unclear whether the effects reported in these studies translate to the general population or even are significant. In summary, additional studies are warranted to evaluate chronic pain management with alternative and combinations of medications in the treatment of chronic pain. |
format | Online Article Text |
id | pubmed-9150009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91500092022-05-31 Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence Edinoff, Amber N. Fort, Juliana M. Singh, Christina Wagner, Sarah E. Rodriguez, Jessica R. Johnson, Catherine A. Cornett, Elyse M. Murnane, Kevin S. Kaye, Adam M. Kaye, Alan D. Neurol Int Review With emerging information about the potential for morbidity and reduced life expectancy with long-term use of opioids, it is logical to evaluate nonopioid analgesic treatments to manage pain states. Combinations of drugs can provide additive and/or synergistic effects that can benefit the management of pain states. In this regard, tetrahydrocannabinol (THC) and cannabidiol (CBD) modulate nociceptive signals and have been studied for chronic pain treatment. Psilocybin, commonly known as “magic mushrooms”, works at the serotonin receptor, 5-HT(2A). Psilocybin has been found in current studies to help with migraines since it has a tryptamine structure and works similarly to triptans. Psilocybin also has the potential for use in chronic pain treatment. However, the studies that have looked at alternative plant-based medications such as THC, CBD, and psilocybin have been small in terms of their sample size and may not consider the demographic or genetic differences in the population because of their small sample sizes. At present, it is unclear whether the effects reported in these studies translate to the general population or even are significant. In summary, additional studies are warranted to evaluate chronic pain management with alternative and combinations of medications in the treatment of chronic pain. MDPI 2022-05-18 /pmc/articles/PMC9150009/ /pubmed/35645354 http://dx.doi.org/10.3390/neurolint14020035 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Edinoff, Amber N. Fort, Juliana M. Singh, Christina Wagner, Sarah E. Rodriguez, Jessica R. Johnson, Catherine A. Cornett, Elyse M. Murnane, Kevin S. Kaye, Adam M. Kaye, Alan D. Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence |
title | Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence |
title_full | Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence |
title_fullStr | Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence |
title_full_unstemmed | Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence |
title_short | Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence |
title_sort | alternative options for complex, recurrent pain states using cannabinoids, psilocybin, and ketamine: a narrative review of clinical evidence |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150009/ https://www.ncbi.nlm.nih.gov/pubmed/35645354 http://dx.doi.org/10.3390/neurolint14020035 |
work_keys_str_mv | AT edinoffambern alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence AT fortjulianam alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence AT singhchristina alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence AT wagnersarahe alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence AT rodriguezjessicar alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence AT johnsoncatherinea alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence AT cornettelysem alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence AT murnanekevins alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence AT kayeadamm alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence AT kayealand alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence |